恢复期血浆治疗因 TRALI 导致的 COVID-19 合并 ARDS。
Convalescent plasma for COVID-19 complicated by ARDS due to TRALI.
机构信息
Internal Medicine, Northwell Health, Great Neck, New York, USA
Internal Medicine, Northwell Health, Great Neck, New York, USA.
出版信息
BMJ Case Rep. 2021 Jan 28;14(1):e239762. doi: 10.1136/bcr-2020-239762.
Abstract
Convalescent plasma, which contains antibodies from recovered individuals, has been used as an effective treatment for infectious diseases in the past and is currently being used as a potential treatment option for COVID-19. Multiple studies have reported this treatment to be safe. We report a case of a patient who developed acute respiratory distress syndrome (ARDS) with features suggestive of transfusion-related acute lung injury after being treated with convalescent plasma for COVID-19. We emphasise the need to be aware of the potential risk of transfusion reactions and disease worsening with convalescent plasma administration and to weigh the risk and benefits of this therapy before administration to patients and propose that further study be done regarding the potential risks of convalescent plasma.
摘要
恢复期血浆含有来自康复患者的抗体，过去曾被用作治疗传染病的有效方法，目前也被用作治疗 COVID-19 的一种潜在治疗选择。多项研究报告称这种治疗方法是安全的。我们报告了一例患者，该患者在接受 COVID-19 的恢复期血浆治疗后出现急性呼吸窘迫综合征（ARDS），并具有提示输血相关急性肺损伤的特征。我们强调需要注意使用恢复期血浆治疗可能会出现输血反应和病情恶化的潜在风险，并在向患者使用该疗法之前权衡其风险和益处，我们还建议进一步研究恢复期血浆的潜在风险。
相似文献
1
Convalescent plasma for COVID-19 complicated by ARDS due to TRALI.恢复期血浆治疗因 TRALI 导致的 COVID-19 合并 ARDS。
BMJ Case Rep. 2021 Jan 28;14(1):e239762. doi: 10.1136/bcr-2020-239762.
2
Transfusion-related acute lung injury in a COVID-19-positive convalescent plasma recipient: a case report.COVID-19 阳性恢复期血浆受者发生输血相关的急性肺损伤：病例报告。
J Int Med Res. 2021 Aug;49(8):3000605211032814. doi: 10.1177/03000605211032814.
3
SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma Donors.SARS-CoV-2 触发恢复期血浆捐献者产生 I 类和 II 类 HLA 抗体。
Intervirology. 2022;65(4):230-235. doi: 10.1159/000524016. Epub 2022 Apr 4.
4
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.5 例危重症 COVID-19 患者接受恢复期血浆治疗。
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
5
Convalescent Plasma Lowered Risk of Death in COVID-19 ARDS.恢复期血浆降低了新冠病毒感染相关急性呼吸窘迫综合征患者的死亡风险。
JAMA. 2023 Nov 28;330(20):1945. doi: 10.1001/jama.2023.21872.
6
ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids.中期妊娠 COVID-19 相关急性呼吸窘迫综合征：血浆输注和皮质类固醇治疗成功。
J Matern Fetal Neonatal Med. 2022 Aug;35(16):3040-3043. doi: 10.1080/14767058.2020.1797669. Epub 2020 Jul 26.
7
Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome.恢复期血浆疗法治疗急性呼吸窘迫综合征的重症 COVID-19 患者的疗效和安全性。
Int Immunopharmacol. 2021 Apr;93:107239. doi: 10.1016/j.intimp.2020.107239. Epub 2020 Dec 2.
8
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.恢复期血浆/甲磺酸卡莫司他用于早期SARS-CoV-2 Q-PCR阳性高危个体（RES-Q-HR）：一项随机对照试验研究方案的结构化总结
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
9
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.新冠康复者血浆或超免疫球蛋白用于新冠患者：快速综述
Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600.
10
Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.恢复期血浆治疗 SARS-CoV-2 相关急性呼吸窘迫综合征的儿科患者。
Pediatr Blood Cancer. 2020 Nov;67(11):e28693. doi: 10.1002/pbc.28693. Epub 2020 Sep 4.
引用本文的文献
1
Combined immunization with SARS-CoV-2 spike and SARS-CoV nucleocapsid protects K18-hACE2 mice but increases lung pathology.将严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白和严重急性呼吸综合征冠状病毒（SARS-CoV）核衣壳蛋白联合免疫可保护K18-hACE2小鼠，但会加重肺部病理变化。
NPJ Vaccines. 2025 Feb 13;10(1):30. doi: 10.1038/s41541-025-01085-1.
2
COVID-19 and Pregnancy: An Updated Review about Evidence-Based Therapeutic Strategies.新型冠状病毒肺炎与妊娠：基于证据的治疗策略最新综述
J Pers Med. 2023 Jun 23;13(7):1035. doi: 10.3390/jpm13071035.
3
Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.了解新冠疫苗和治疗方案面临的挑战、群体免疫以及再次感染的可能性。
J Taibah Univ Med Sci. 2023 Jun;18(3):600-638. doi: 10.1016/j.jtumed.2022.11.007. Epub 2022 Dec 17.
4
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.针对 SARS-CoV-2 的被动免疫疗法：从基于血浆的疗法到单一强效抗体，以在与变异体的竞赛中保持领先地位。
BioDrugs. 2022 May;36(3):231-323. doi: 10.1007/s40259-022-00529-7. Epub 2022 Apr 27.
5
Why Does the Precautionary Principle Suffice for Blood Regulation?为什么预防原则足以规范血液？
Pharmaceut Med. 2021 Sep;35(5):281-286. doi: 10.1007/s40290-021-00400-0. Epub 2021 Sep 7.
6
The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的出现及恢复期血浆疗法在感染管理中的作用
Life (Basel). 2021 Jul 23;11(8):734. doi: 10.3390/life11080734.
7
Longevity of seropositivity and neutralizing antibodies in recovered MERS patients: a 5-year follow-up study.MERS 患者恢复期血清学阳性和中和抗体的持久性：一项 5 年随访研究。
Clin Microbiol Infect. 2022 Feb;28(2):292-296. doi: 10.1016/j.cmi.2021.06.009. Epub 2021 Jun 14.
本文引用的文献
1
Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.基于其他严重呼吸道病毒感染的证据评估恢复期血浆治疗严重 COVID-19 的疗效和安全性：系统评价和荟萃分析。
CMAJ. 2020 Jul 6;192(27):E745-E755. doi: 10.1503/cmaj.200642. Epub 2020 May 22.
2
The role of passive immunization in the age of SARS-CoV-2: an update.被动免疫在 SARS-CoV-2 时代的作用：更新。
Eur J Med Res. 2020 May 13;25(1):16. doi: 10.1186/s40001-020-00414-5.
3
Acute respiratory failure in COVID-19: is it "typical" ARDS?新型冠状病毒肺炎所致急性呼吸衰竭：是“典型”的急性呼吸窘迫综合征吗？
Crit Care. 2020 May 6;24(1):198. doi: 10.1186/s13054-020-02911-9.
4
Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.中国武汉 COVID-19 患者恢复期血浆治疗。
J Med Virol. 2020 Oct;92(10):1890-1901. doi: 10.1002/jmv.25882. Epub 2020 Jun 29.
5
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.5 例危重症 COVID-19 患者接受恢复期血浆治疗。
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
6
The convalescent sera option for containing COVID-19.使用康复期血清来控制新型冠状病毒肺炎。
J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.
7
Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone.在塞拉利昂弗里敦对恢复期全血治疗埃博拉病毒病的评估。
J Infect. 2017 Mar;74(3):302-309. doi: 10.1016/j.jinf.2016.11.009. Epub 2016 Nov 17.
8
Possible Transfusion-Related Acute Lung Injury Following Convalescent Plasma Transfusion in a Patient With Middle East Respiratory Syndrome.中东呼吸综合征患者恢复期血浆输注后可能发生的输血相关急性肺损伤
Ann Lab Med. 2016 Jul;36(4):393-5. doi: 10.3343/alm.2016.36.4.393.
9
Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain.恢复期血浆使用后发生急性呼吸窘迫综合征：西班牙马德里感染埃博拉病毒疾病患者的治疗。
Lancet Respir Med. 2015 Jul;3(7):554-62. doi: 10.1016/S2213-2600(15)00180-0. Epub 2015 May 31.
10
The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.恢复期血浆和高效免疫球蛋白治疗病毒性病因严重急性呼吸道感染的有效性：系统评价与探索性Meta分析
J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16.
Zotero 插件